Dan Cojocari
Impact in
- Hematology top 10%
- Acute Myeloid Leukemia Research
-
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Protein Degradation and Inhibitors 3
- Ubiquitin and proteasome pathways 1
- Epigenetics and DNA Methylation 1
-
- Acute Myeloid Leukemia Research 5
- Co-authors
- Bradly G. Wouters (6 shared papers)Joel D. Leverson (5 shared papers)Alison P. McGuigan (3 shared papers)Darren C. Phillips (5 shared papers)Julie J. Purkal (4 shared papers)Erwin R. Boghaert (4 shared papers)Radhakrishnan Mahadevan (1 shared paper)Christian Frezza (1 shared paper)
- Journals
- Blood (3 papers)Radiotherapy and Oncology (3 papers)Frontiers in Bioengineering and Biotechnology (1 paper)Frontiers in Oncology (1 paper)Clinical Cancer Research (1 paper)
- Partner nations
- CanadaUnited StatesNetherlands
In The Last Decade
Dan Cojocari
13 papers receiving 527 citations
Peers
Comparison fields: 5 of 68
- Hematology 127
- Cancer Research 76
- Oncology 110
- Genetics 36
- Molecular Biology 243
Countries citing papers authored by Dan Cojocari
This map shows the geographic impact of Dan Cojocari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Cojocari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Cojocari more than expected).
Fields of papers citing papers by Dan Cojocari
This network shows the impact of papers produced by Dan Cojocari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Cojocari. The network helps show where Dan Cojocari may publish in the future.
Co-authors
The 25 scholars most cited alongside Dan Cojocari, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 133 | |
| 2 | 2015 | 106 | |
| 3 | 2011 | 54 | |
| 4 | 2013 | 38 | |
| 5 | 2013 | 35 | |
| 6 | 2019 | 32 | |
| 7 | 2021 | 29 | |
| 8 | 2018 | 27 | |
| 9 | 2018 | 25 | |
| 10 | 2016 | 24 | |
| 11 | 2018 | 23 | |
| 12 | 2019 | 4 | |
| 13 | 2018 | 1 |
About Dan Cojocari
Dan Cojocari is a scholar working on Molecular Biology, Hematology, Biomedical Engineering, Oncology and Cancer Research, having authored 13 papers that have together received 531 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (5 papers), Protein Degradation and Inhibitors (3 papers), Cancer Cells and Metastasis (3 papers), 3D Printing in Biomedical Research (3 papers), Nanoplatforms for cancer theranostics (2 papers), Cancer, Hypoxia, and Metabolism (2 papers), Ubiquitin and proteasome pathways (1 paper) and Epigenetics and DNA Methylation (1 paper). The work is most often cited by research in Hematology (127 citations), Cancer Research (76 citations), Oncology (110 citations), Genetics (36 citations) and Molecular Biology (243 citations). Dan Cojocari has collaborated with scholars based in Canada, United States and Netherlands. Frequent co-authors include Bradly G. Wouters, Joel D. Leverson, Alison P. McGuigan, Darren C. Phillips, Julie J. Purkal, Erwin R. Boghaert, Radhakrishnan Mahadevan, Christian Frezza, Edoardo Gaude and Ravi N. Vellanki. Their work appears in journals such as Blood, Radiotherapy and Oncology, Frontiers in Bioengineering and Biotechnology, Frontiers in Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.